Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Azenta, Inc. - Common Stock (NQ: AZTA )

26.73 +0.93 (+3.60%)
Streaming Delayed Price Updated: 3:15 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 359,531
Open 25.91
Bid (Size) 26.71 (3)
Ask (Size) 26.76 (1)
Prev. Close 25.80
Today's Range 25.82 - 27.02
52wk Range 24.06 - 63.58
Shares Outstanding 12,500,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Cash-Producing Stocks Facing Headwinds
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
3 of Wall Street’s Favorite Stocks in the Doghouse
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory

Performance

YTD
-46.58%
-46.58%
1 Month
-30.08%
-30.08%
3 Month
-50.48%
-50.48%
6 Month
-35.64%
-35.64%
1 Year
-49.12%
-49.12%

More News

Read More
3 Reasons AZTA is Risky and 1 Stock to Buy Instead
Via StockStory
Winners And Losers Of Q4: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks
Via StockStory
A Glimpse Into The Expert Outlook On Azenta Through 4 Analysts
Via Benzinga
Earnings Scheduled For February 5, 2025
Via Benzinga
Unpacking Q4 Earnings: West Pharmaceutical Services (NYSE:WST) In The Context Of Other Drug Development Inputs & Services Stocks
Via StockStory
Drug Development Inputs & Services Stocks Q4 In Review: Medpace (NASDAQ:MEDP) Vs Peers
Via StockStory
Drug Development Inputs & Services Stocks Q4 Results: Benchmarking Fortrea (NASDAQ:FTRE)
Via StockStory
Unpacking Q4 Earnings: UFP Technologies (NASDAQ:UFPT) In The Context Of Other Drug Development Inputs & Services Stocks
Via StockStory
Q4 Earnings Recap: Azenta (NASDAQ:AZTA) Tops Drug Development Inputs & Services Stocks
Via StockStory
1 Small-Cap Stock with Exciting Potential and 2 to Brush Off
Via StockStory
Topics Supply Chain
Exposures Supply Chain
A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack
Via StockStory
Spotting Winners: Charles River Laboratories (NYSE:CRL) And Drug Development Inputs & Services Stocks In Q4
Via StockStory
What To Expect From Fortrea’s (FTRE) Q4 Earnings
Via StockStory
UFP Technologies (UFPT) Reports Q4: Everything You Need To Know Ahead Of Earnings
Via StockStory
Earnings To Watch: Repligen (RGEN) Reports Q4 Results Tomorrow
Via StockStory
Earnings To Watch: Charles River Laboratories (CRL) Reports Q4 Results Tomorrow
Via StockStory
West Pharmaceutical Services (WST) Q4 Earnings Report Preview: What To Look For
Via StockStory
Medpace (MEDP) To Report Earnings Tomorrow: Here Is What To Expect
Via StockStory
Stocks Rebound, Google Eyes Worst Drop In A Year, Gold Shatters Fresh Records: What's Driving Markets Wednesday?
Via Benzinga
Azenta’s (NASDAQ:AZTA) Q4 Sales Top Estimates
Via StockStory
Illumina (ILMN) Reports Earnings Tomorrow: What To Expect
Via StockStory
IQVIA (IQV) Q4 Earnings Report Preview: What To Look For
Via StockStory
Quantum Computing, BlackBerry And Lucid Group Are Among Top Mid Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.